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The recent history of cardiovascular medicine is a remarkable success story. Since the early 
1970s, total cardiovascular mortality in Europe and the United States declined on average 50% 
for both men and women.1 In the United Kingdom alone, approximately 70,000 deaths were 
prevented or postponed between 1980 and 2000.2 Although this decline started approximately 25 
years later in Eastern European countries, cardiovascular mortality in Eastern Europe has also 
been steadily decreasing since the 1990s.3 
 
Much of the observed decline in cardiovascular mortality has been attributed to public health 
approaches and primary prevention. Improvements in population level risk factors such as 
smoking cessation, and blood pressure and cholesterol control have been shown to be 
responsible for more than half of the reductions in cardiovascular mortality over the past two 
decades.4 Significant advances in medical and surgical treatments have accounted for the 
remaining 40-45% of the total mortality decrease.5,6 In particular, secondary preventive therapies 
after myocardial infarction or revascularization, initial treatments for acute myocardial infarction 
or unstable angina, treatments for heart failure, and revascularization for chronic angina have 
contributed to major improvements.   
 
Despite these major successes, the burden of cardiovascular disease remains significant. 
According to the most recent Global Burden of Disease study, ischemic heart disease and stroke 
account for the majority of deaths around the world.7 In 2013, approximately one third of all 
deaths (~17 million) were attributable to cardiovascular disease – a 35% increase since 1990.8 
Globally, cardiovascular diseases are afflicting ever-increasing numbers of young and middle-
aged adults. This is especially so in low and middle income countries that are faced with the 
double burden of communicable and non-communicable diseases to which cardiovascular 
illnesses contribute significantly.9 Nearly 80% of the world's more than 1 billion smokers live in 
low- and middle-income countries.10 Respectively, ischemic heart disease and stroke are 
responsible for the first and third highest numbers of years of life lost and disability-adjusted life 
years worldwide, replacing childhood conditions from 1990 to 2010.11  
 
In addition to such significant burden of mortality and morbidity, cardiovascular diseases face 
important quality challenges that extend beyond the traditional boundaries of medical science 
and practice. For example, there are substantial and quantifiable equity issues: cardiovascular 
mortality is higher in people with low education, income, social class or those in marginalized 
ethnic groups and those living in poor and deprived communities.9 There are also complex 
behavioral issues: patients rarely adhere to their medications and there is a significant decline in 
the use of medications after treatment initiation.12 As a result, a large proportion of individuals 
have cardiovascular risk factors that remain uncontrolled despite the availability of proven, 
effective, and often inexpensive therapies.13  
 
Economic, workforce-related, and political challenges around the world are straining 
government budgets, and putting unprecedented pressure on health care delivery systems. 
Currently, the quality of cardiovascular care delivery remains sub-optimal even in some of the 
richest parts of the world.14 There is now a chasm between what should happen versus what 
does happen in health care systems. Despite the recent emergence of health technology 
assessment and clinical practice guideline development efforts over the past decades, observed 
differences between evidence-based recommendations and their implementation – the so-called 
evidence-practice gaps – are widespread.15 While health care systems heavily invest in efforts to 
ensure appropriate provision and use of technologies and services, under-use and over-use 
problems continue to co-exist side-by-side.16 There is both a lack of implementation of some 
proven effective strategies, and also inappropriate use of strategies with strong evidence against, 
or insufficient evidence for their effectiveness and safety.  
 
A new future in cardiovascular medicine 
Tackling these challenges is not straightforward and warrants innovative policy and management 
responses. A new generation of leaders from within the profession can devise creative solutions 
and transform the future of cardiovascular medicine. Key insights from social and behavioral 
sciences can help towards this goal. Over the past decades, cardiovascular medicine has served as 
an incubator for developing and testing innovative policy mechanisms in health care such as pay-
for-performance.17 This is perhaps unsurprising as several cardiovascular outcomes are relatively 
easy to capture in routinely collected administrative databases and thus amenable to monitoring, 
measurement, and accountability. In fact, many quality improvement interventions that are 
commonplace today (e.g., public reporting of outcome data) were first developed, tested and 
subsequently rolled out in cardiovascular medicine.18  
 
The reach of policy and economics in cardiovascular medicine is far and wide.19 As new 
innovative medical and surgical interventions are approved or adopted, their affordability is 
almost as widely discussed and debated as their health benefits and safety. Questions to which 
the fields of health policy and economics can help answer are several and include: How are funds 
collected, pooled and allocated in health care systems? What are the implications of different 
health financing mechanisms? What are the advantages and disadvantages of the current 
processes for medical technology approval and reimbursement? Which population sub-groups 
are eligible to receive care and at what cost? What type of evidence is used to inform practice 
guidelines and quality indicators that increasingly form the basis of physician compensation?  
 
As an increasing number of countries experiment with new policy mechanisms aimed at 
improving quality and access, and containing costs, cardiovascular experts are best suited to join 
forces with health services researchers, managers, economists, and policymakers to inform the 
design, implementation and evaluation of future interventions. An interdisciplinary training 
program can help ensure that stakeholders from different perspectives and backgrounds adopt a 
common language when discussing current issues and considering alternative solutions.  
 
An innovative program for future leaders in cardiovascular medicine 
The European Heart Academy of the European Society of Cardiology has joined forces with the 
London School of Economics and Political Science (LSE), a global leader in social sciences 
research and teaching, to develop and deliver a unique Master’s degree program on health 
economics, policy and outcomes research aimed at health care professionals in cardiovascular 
sciences with full-time employment (Box).  
 
Currently in its 3rd year, the master’s level program has already trained approximately 80 
cardiovascular specialists from over 20 countries. The program has a carefully crafted curriculum 
to ensure that health care professionals in the cardiovascular medicine field gain a 
complementary set of skills to their specialized training in clinical medicine. In addition to 
compulsory courses focused on quality, economics, and policy, a range of optional modules 
tackle not only today’s challenges like management and health technology assessment but also 
tomorrow’s opportunities such as behavioral science and performance measurement in a fast-
changing health care environment (Table).  
 
With advanced training in outcomes research, policy, and health economics, course participants 
leave the program equipped with key skills to become the future champions of policy and 
management change in their clinics, hospitals, national and regional health systems, regulatory 
authorities and even at the world stage. An expanding network of graduates are expected to take 
on roles in guideline development panels, health technology assessment committees, public-
private research initiatives, consulting companies, and pharmaceutical, medical device, biotech, 
and big data and data analytics industries.20,21  
 
Conclusion 
As health care costs continue to rise, cardiovascular medicine will undisputedly come under 
greater scrutiny over the next decade. LSE’s inter-disciplinary post-graduate training program 
developed in collaboration with the ESC is aimed at equipping health care professionals within 
cardiovascular medicine with a highly relevant skillset in social sciences. With such training, 
researchers and practitioners from within the profession have an opportunity to become active 
voices and role models in discussions that affect every corner of medicine and its practice.   
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Box: Origin and evolution of the program 
 The idea for the Executive MSc in Health Economics, Outcomes and Management in 
Cardiovascular Sciences was conceived jointly by Professors Elias Mossialos and Panos 
Vardas in 2014.  
 The vision behind the program was to equip cardiovascular specialists with essential 
research and policy skills to make active contributors to health policy discussions.  
 To implement this vision, a working group was immediately formed and included Huseyin 
Naci and Paulus Kirchhof in addition to Panos Vardas and Elias Mossialos.  
 The working group collaborated on designing a curriculum and establishing an innovative 
set of modules and assessments.  
 Following the program’s successful launch in December 2015 with its first intake of 39 
students, a Steering Committee was formed to monitor the program’s implementation and 
identify opportunities for participants. The current Steering Committee includes Panos 
Vardas (Past President of ESC and Chief Strategy Officer of EHA), Alec Vahanian (Chair 
of EHA), Isabel Bardinet (Executive Director of ESC), Huseyin Naci (MSc Program Co-
Director, LSE), Mark Maloney (Head of Academic Partnerships, LSE), and Elias 
Mossialos (MSc Program Co-Director, LSE).  
 In its first 2 years, the program has attracted high-profile speakers including Jeroen Bax 
(President of ESC), Sir Professor Julian LeGrand (Former Senior Advisor to Tony Blair), 
Leeza Osipenko (Director of Scientific Advice, National Institute for Health and Care 
Excellence), Dr Matt Kearney (National Clinical Director for Cardiovascular Disease 
Prevention, NHS England), and Professor Tony Rudd (National Clinical Director for 
Stroke, NHS England).  
 
Table: Program structure and overview of modules 
Compulsory Modules Optional Modules (Required to take 3 of 6) 
Quality and Outcomes in Cardiovascular Sciences 
 Provides an overview of the concept of quality, its 
key components, and its measurement in different 
health care systems.  
 Offers a critical perspective on the literature 
evaluating quality improvement interventions 
focused on the cardiovascular disease field.  
Measuring Health System Performance  
 Presents a framework to discuss the opportunities 
and challenges with performance measurement in 
health care. 
 Focuses on the measurement instruments and 
analytic tools needed for performance 
measurement.  
Economic Analysis for Health Policy 
 Serves as an introduction to major developments 
in the economics of health and health care.  
 Provides health care professionals with a strong 
understanding of the role economics can play in 
health policy and health system administration 
Financing Health Care 
 Gives a thorough grounding in health financing 
policy.  
 Focuses on the health financing functions of 
collecting revenue, pooling funds and purchasing 
services, as well as on policy choices concerning 
coverage, resource allocation and provider 
payment mechanisms.  
Systematic Review and Meta-analysis 
 Covers the principles of reviewing and synthesizing 
the existing body of literature.  
 Provides an overview of methods for quantitatively 
synthesizing multiple randomized controlled trials 
in meta-analysis.  
Research Design for Evaluating Health Programs 
and Policies 
 Provides a practical overview of the principles and 
models of evaluation, and the role of theories, 
concepts, and hypotheses.  
 Covers study design choices in light of bias, 
validity and other design trade-offs.  
Economic Evaluation in Health Care 
 Focuses on analytic methods in the economic 
evaluation of health interventions.  
 Provides a strong foundation in cost-effectiveness 
analysis of interventions used in long-term chronic 
illnesses.  
Behavioral Science for Health 
 Introduces the main tools and principles of 
behavioural sciences and the key state-of-the-art 
applications to health economics, policy, and 
management.  
 Applies behavioural science tools to concrete 
challenges in the health area.  
Using Health Economics to Analyse and Inform 
Policy and Practice 
 Gives an overview on how health systems are 
constructed, and how the various parts of the 
system interact. 
 Focuses on the role of regulation, resource 
allocation, payment arrangements, and the 
complexities of evaluating policy and performance.  
Principles of Health Technology Assessment 
 Introduces the role of Health Technology 
Assessment in health care reimbursement and 
coverage decision making.  
 Covers the key operational modalities of Health 
Technology Assessment, the different models of 
value assessment and how they link to decision-
making. 
Dissertation 
 Offers an opportunity to carry out independent 
study.  
 Integrates approaches and knowledge learned 
across courses and present results to address a 
health/clinical policy. 
Introduction to Management in Health Care 
 Introduces the main principles of management and 
strategy and related issues that impact on 
organisational change, group decision making, 
innovation and leadership.  
 Applies academic management knowledge to 
health care practice.  
 
